Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer
Metrics: PDF 1631 views | HTML 2562 views | ?
Huihong Jiang1,*, Huaguang Li2,*, Ajian Li3, Erjiang Tang2, Dan Xu2, Yin Chen2, Yong Zhang3, Min Tang3, Zhiyong Zhang4, Xiaxing Deng1, Moubin Lin2,3
1Department of General Surgery, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
2Center for Translational Medicine, Yangpu Hospital Affiliated to Shanghai Tongji University School of Medicine, Shanghai, China
3Department of General Surgery, Yangpu Hospital Affiliated to Shanghai Tongji University School of Medicine, Shanghai, China
4Department of General Surgery, Zhuji People's Hospital of Zhejiang Province, Zhejiang, China
*These authors have contributed equally to this work
Moubin Lin, email: [email protected]
Xiaxing Deng, email: [email protected]
Keywords: colorectal cancer, HALP, prognostic, risk, survival
Received: June 07, 2016 Accepted: September 16, 2016 Published: September 27, 2016
More than 50% of patients with colorectal cancer (CRC) are initially diagnosed with locally advanced CRC (LACRC), and half of those patients develop recurrence or metastasis after resection. Here, we investigated whether the novel index HALP, which is a combination of preoperative hemoglobin, albumin, lymphocyte and platelet levels, correlates with survival in LACRC patients. A total of 820 patients with LACRC from two independent hospitals were included in our study. The correlations between HALP and overall and cancer-specific survival were calculated using training and validation sets. Lower HALP values correlated with an increased risk of death and cancer-related death in both sets. Moreover, the risk score based on HALP allowed stratification of patients into distinct prognostic groups with greater accuracy than previously proposed indexes. These results suggest that HALP may be useful as a clinical prognostic factor for patients with LACRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.